Transcatheter aortic valve implantation using the SAPIEN 3 valve to treat aortic regurgitation: The French multicentre S3AR study
Archives of Cardiovascular Diseases · 2023-02 · 116 (2) · 98-105
DOI: 10.1016/j.acvd.2022.12.003 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Archives of Cardiovascular Diseases, 2023-02. Verfasst von Clémence Delhomme und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bichat Hospital, AP-HP, Inserm U 1148, University of Paris, 75018 Paris, France. Electronic address: clemence.delhomme@aphp…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Insufficiency, Aortic Valve Stenosis, Heart Valve Prosthesis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Transcatheter aortic valve implantation now has a major role in the treatment of patients with severe aortic stenosis. However, evidence is scarce on its feasibility and safety to treat patients with pure aortic regurgitation. AIMS: We sought to evaluate the results of transcatheter aortic valve implantation using the balloon-expandable SAPIEN 3 transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA) in patients with pure aortic regurgitation on native non-calcified valves. METHODS: We conducted a retrospective and prospective French multicentre observational study. We included all patients with symptomatic severe pure aortic regurgitation on native non-calcified valves, contraindicated to or at high risk for surgical valve replacement, who underwent transcatheter aortic valve implantation using the SAPIEN 3 transcatheter heart valve. RESULTS: A total of 37 patients (male sex, 73%) with a median age of 81years (interquartile range 69-85years) were screened using transthoracic echocardiography and computed tomography and were included at eight French centres. At baseline, 83.8% of patients (n=31) had dyspnoea New York Heart Association class≥III. The device success rate was 94.6% (n=35). At 30days, the all-cause mortality rate was 8.1% (n=3) and valve migration occurred in 10.8% of cases (n=4). Dyspnoea New York Heart Association class≤II was seen in 86.5% of patients (n=32), and all survivors had aortic regurgitation grade≤1. At 1-year follow-up, all-cause mortality was 16.2% (n=6), 89.7% (n=26/29) of survivors were in New York Heart Association class≤II and all had aortic regurgitation grade≤2. CONCLUSION: Transcatheter aortic valve implantation using the SAPIEN 3 transcatheter heart valve seems promising to treat selected high-risk patients with pure aortic regurgitation on non-calcified native valves, contraindicated to surgical aortic valve replacement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Bichat Hospital, AP-HP, Inserm U 1148, University of Paris, 75018 Paris, France. Electronic address: clemence.delhomme@aphp.fr.
- Department of Cardiology, Bichat Hospital, AP-HP, Inserm U 1148, University of Paris, 75018 Paris, France.
- Medipôle Lyon-Villeurbanne, 69100 Villeurbanne, France.
- Rangueil Hospital, 31400 Toulouse, France.
- Strasbourg University Hospital, 67000 Strasbourg, France.
- Hôpital Cardiologique et Pneumologique Louis-Pradel, Hospices Civils de Lyon, 69500 Bron, France.
Zitieren
APA
Delhomme, C., Urena, M., Zouaghi, O., Campelo-Parada, F., Ohlmann, P., Rioufol, G., Van Belle, E., Pinaud, F., Meneveau, N., Staat, P., Morel, O., Derimay, F., Vincent, F., Rouleau, F., Brochet, E., Chong-Nguyen, C., & Himbert, D. (2023). Transcatheter aortic valve implantation using the SAPIEN 3 valve to treat aortic regurgitation: The French multicentre S3AR study. Archives of Cardiovascular Diseases, 116(2), 98-105. https://doi.org/10.1016/j.acvd.2022.12.003
Vancouver
Delhomme C, Urena M, Zouaghi O, Campelo-Parada F, Ohlmann P, Rioufol G, et al. Transcatheter aortic valve implantation using the SAPIEN 3 valve to treat aortic regurgitation: The French multicentre S3AR study. Archives of Cardiovascular Diseases. 2023;116(2):98-105. doi:10.1016/j.acvd.2022.12.003
BibTeX
@article{Delhomme2023,
author = {Delhomme, Clémence and Urena, Marina and Zouaghi, Oualid and Campelo-Parada, Francisco and Ohlmann, Patrick and Rioufol, Gilles and Van Belle, Eric and Pinaud, Frédéric and Meneveau, Nicolas and Staat, Patrick and Morel, Olivier and Derimay, François and Vincent, Flavien and Rouleau, Frédéric and Brochet, Eric and Chong-Nguyen, Caroline and Himbert, Dominique},
title = {Transcatheter aortic valve implantation using the SAPIEN 3 valve to treat aortic regurgitation: The French multicentre S3AR study},
journal = {Archives of Cardiovascular Diseases},
year = {2023},
volume = {116},
number = {2},
pages = {98--105},
doi = {10.1016/j.acvd.2022.12.003}
}
EUVIMED